Today: 11 June 2026
Bitcoin price today: BTC slips toward $87,700 as year-end risk mood drags crypto stocks

Bitcoin price today: BTC slips toward $87,700 as year-end risk mood drags crypto stocks

NEW YORK, December 31, 2025, 17:34 ET — After-hours

  • Bitcoin was down about 0.7% near $87,700 in late U.S. trading, on track for a 2025 loss.
  • U.S. spot bitcoin ETFs logged about $355 million of net inflows on Dec. 30, Farside Investors data showed.
  • Crypto-linked shares including Strategy and Coinbase were lower in after-hours trading.

Bitcoin was down 0.7% at $87,696 on Wednesday, extending a late-year drift that has left the token on track for its first annual loss since 2022.

The year-end slide matters because the market has been treating bitcoin more like a “risk asset” — the kind that often falls when investors cut exposure to stocks and other higher-risk trades. Analysts say that link to equities could tighten further in 2026 as traders focus on interest-rate expectations and valuations in AI-related shares. Investing

U.S. stocks ended the final session of 2025 lower, and trading volumes stayed thin into the New Year holiday, a backdrop that can magnify moves across markets that rely on steady liquidity.

Bitcoin traded between $87,173 and $89,014 on the day, while ether, the second-largest cryptocurrency, was up 0.3% at $2,976.

Crypto-linked U.S. stocks tracked the softer tone after the bell. Strategy was down about 2.3% and Coinbase fell 2.4% in after-hours trading, while miners Marathon Digital slid 3.6% and Riot Platforms eased 0.4%.

The pullback caps a year of sharp swings. Bitcoin surged earlier in 2025 after the election of U.S. President Donald Trump, then fell alongside stocks after tariff headlines, before rebounding to an all-time high above $126,000 in early October.

Days later, the market sold off again after Trump announced a new tariff on Chinese imports and threatened export controls on critical software, Reuters reported. That triggered more than $19 billion of “liquidations” — forced selling when leveraged traders can’t meet margin calls — across crypto positions. Investing

“In 2025, the market showed that bitcoin increasingly exhibits the characteristics of a risk asset,” said Linh Tran, a senior market analyst at XS.com, pointing to a stronger correlation with U.S. equities. Investing

Flows into regulated products offered one of the few bright spots into year-end. U.S. spot bitcoin ETFs — funds that hold bitcoin directly and trade like stocks — posted $355.1 million of net inflows on Dec. 30, snapping a seven-session run of outflows, according to Farside Investors.

BlackRock’s iShares Bitcoin Trust (IBIT) led with $143.7 million, while Ark 21Shares’ ARKB drew $109.6 million and Fidelity’s FBTC took in $78.6 million, the same data showed.

Policy remains a key overhang for 2026. The crypto industry has scored regulatory wins in Washington, including the SEC’s move to dismiss lawsuits against Coinbase and Binance and the passage of a law setting federal rules for dollar-pegged tokens, known as stablecoins, Reuters reported. Investors are still waiting for broader market-structure legislation that could reshape how crypto platforms are regulated.

Traders are watching whether bitcoin can reclaim the $90,000 level as liquidity returns after the holiday break, and whether ETF inflows hold up in early January. A sharp shift in U.S. rates or trade-policy messaging could set the tone, with near-term support seen around Wednesday’s $87,173 low.

Stock Market Today

  • Cerebras Systems Shares Rise 4.64% on Morgan Stanley Buy Rating
    June 10, 2026, 10:46 PM EDT. Cerebras Systems Inc. (NASDAQ:CBRS) gained 4.64% to close at $237.33 after Morgan Stanley issued a buy rating and set a $250 price target, signaling a 5% upside. The investment bank highlighted Cerebras as a standout in AI infrastructure, with a unique position in low-latency inference hardware-a growing market segment. The company, listed on May 14 at $185, has already surged 28%. Morgan Stanley cited a strong contracted backlog of 750 MW capacity agreements supporting future growth. Despite CBRS's momentum, some investors may find other AI stocks more attractive due to greater upside or lower risk profiles.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop